ClinicalTrials.gg
Sign In
Drug

Pirtobrutinib clinical trials

Also written LOXO-305, LY3527727 and Jaypirca.

studies test it
65
open now
38
in phase 3
7
first study started
2019

How each study uses pirtobrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pirtobrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Jan 2023 · JAYPIRCA · NDA 216059 (FDA, Drugs@FDA)
European Union
30 Oct 2023 · Jaypirca · EMEA/H/C/005863 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pirtobrutinib
56
BTK Inhibitor LOXO-305
5
5-Amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-((2S)-1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
4
LOXO-305, LY3527727
2

Brand

Jaypirca
12

Development codes

LOXO-305
31
LY3527727
28

Studies by the year they started

65 studies that test it; most in 2025 (16)

Studies that test pirtobrutinib, by start year
YearStudies
20191
20208
202110
20224
20234
20247
202516
202615

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
18
Phase 2
39
Phase 3
7
Phase 4
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Leukemia, Lymphocytic, Chronic, B-Cell
20
Lymphoma, Mantle-Cell
9
Waldenstrom Macroglobulinemia
3
Lymphoma, B-Cell
3
Renal Insufficiency
1
Hepatic Insufficiency
1
Purpura, Thrombocytopenic, Idiopathic
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Leukemia
1
Multiple Sclerosis
1

Who runs them

Industry 30 · Other 35

Eli Lilly and Company (17) · Loxo Oncology, Inc. (11) · M.D. Anderson Cancer Center (6) · University of Utah (2) · Ruijin Hospital (2) · Changzhou No.2 People's Hospital (2) · Dana-Farber Cancer Institute (1) · Mayo Clinic (1)

Often tested with

Tested in the same studies.

Rituximab (6) · Venetoclax (6) · Epcoritamab (2) · Mosunetuzumab (2) · Polatuzumab vedotin (2) · Obinutuzumab (2) · Glofitamab (2) · Sintilimab (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Pirtobrutinib is the comparator. A study of two new drugs counts under both.

  • 1Mesutoclax · Beijing InnoCare Pharma Tech Co., Ltd. · next primary completion Oct 2032
  • 1Rocbrutinib · Newave Pharmaceutical Inc · next primary completion Oct 2029
  • 1Tacabrutideg · BeOne Medicines · next primary completion Apr 2028
Reaching primary completion within a year · 8, 2 in phase 3

Studies that test pirtobrutinib, phase 3 first.

Studies

Open first, then newest update. How each study uses pirtobrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 65

See all 65 studies that test pirtobrutinib →

Given beside what is tested · 6 — pirtobrutinib is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with pirtobrutinib

Codes

What other systems call pirtobrutinib · ClinicalTrials.gg INT001935

  • MeSH (NLM) C000723100pirtobrutinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) JNA39I7ZVBPIRTOBRUTINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q116622551pirtobrutinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C158617PirtobrutinibOne source FDA
  • DrugBank DB17472One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.